Timothy Collins, MD
Family Medicine · Etowah, TNNPI 1235126392
Payments from drug & device makers
Across 536 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- AbbVie$616
- Boehringer Ingelheim$605
- Bayer$557
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,777100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 91 | $1,505 |
| Novo Nordisk | 84 | $1,379 |
| AstraZeneca | 59 | $1,014 |
| AbbVie(2 entities) | 39 | $616 |
| Boehringer Ingelheim | 38 | $605 |
| Bayer | 33 | $557 |
| Pfizer | 31 | $512 |
| Johnson & Johnson | 19 | $285 |
| Novartis | 17 | $269 |
| Amgen | 15 | $263 |
| Sanofi-aventis U.S. LLC | 15 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $226 |
| Merck | 14 | $221 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $198 |
| Abbott | 6 | $124 |
| Kowa Pharmaceuticals America, Inc. | 6 | $104 |
| GSK | 6 | $97 |
| Xeris Pharmaceuticals, Inc. | 5 | $95 |
| Medtronic | 5 | $90 |
| Exact Sciences | 3 | $58 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Eisai Inc. | 3 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
How this compares
$8,816 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $150,232 |
| EliquisApixaban | 99 | $133,337 |
| MounjaroTirzepatide | 82 | $101,778 |
| JardianceEmpagliflozin | 98 | $100,355 |
| XareltoRivaroxaban | 91 | $89,642 |
| FarxigaDapagliflozin Propanediol | 54 | $70,909 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $56,567 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $48,730 |
| TrulicityDulaglutide | 29 | $48,132 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $45,491 |
| JanuviaSitagliptin Phosphate | 43 | $44,681 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $37,650 |
| MyrbetriqMirabegron | 38 | $36,400 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $29,072 |
| LinzessLinaclotide | 27 | $24,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,379 | $150,232131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,505 | $149,910111 claims |
| PfizerEliquis | $512 | $133,33799 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,014 | $123,546124 claims |
| Boehringer IngelheimJardiance | $605 | $100,35598 claims |
| Johnson & JohnsonXarelto | $285 | $89,64291 claims |
| GSKTrelegy Ellipta | $97 | $56,56776 claims |
| MerckJanuvia, Belsomra | $221 | $52,31056 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $236 | $41,84864 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $36,40038 claims |
| AbbVieLinzess, Synthroid | $616 | $27,06775 claims |
| NovartisEntresto | $269 | $22,35123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Etowah
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.